about
[Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)].[Treatment with natural interferon (alfaferone) in clinical practice--our experience].Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experienceVirological response to treatment with peginterferon alfa-2a in adolescents with chronic hepatitis B.Distribution of HCV genotypes in the populations of inmates in polish prison potulice and patients hospitalised in bydgoszcz.Acute liver failure caused by concurrent autoimmune hepatitis and hepatitis B in a 16-year old girl.Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C InfectionHBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B.[Incidence of familial viral hepatitis (VH): data of the Infectious Disease Clinic in Bydgoszcz]Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment.A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel.Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.[Organization of health care for persons from the groups of high risk of HIV infection in Bydgoszcz]Forecasting the disease burden of chronic hepatitis C virus in Poland.Distribution of HCV genotypes in Poland.Vertical genotype 1 HCV infection treated successfully in the second year of life: a case report.[Clinical picture of certain hemorrhagic fever diseases]Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial.Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection.Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.Hepatitis C virus (HCV) serotype in the asymptomatic HCV-infected patients from selected groups.Prevalence and risk factors of HCV infection in Poland.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.[Errors in the diagnosis of chronic intrahepatic cholestasis]Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients.Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.[Serological markers of selected viral infections transmitted by parenteral route in drug addicts][Serum neopterin and beta2-microglobulin concentration as "prognostic markers" of AIDS].[Tuberculin reactions in patients with acute viral hepatitis (author's transl)][Plasma selenium concentration, glutathione peroxidase and glutathione S-transferase activities in patients with chronic liver diseases].Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases.[Results of the treatment of chronic hepatitis B with interferon alfa (wellferon)][Hepatitis C (personal observations].Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes.Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin[Thyrotoxicosis induced by interferonotherapy of chronic hepatitis C in a woman with Hashimoto's thyroiditis].[Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study.Interferon-induced thyroiditis during treatment of chronic hepatitis C.
P50
Q33370029-7E7CFA8C-A906-4BF5-8BC3-BF1D5026E4E7Q33376267-62EC357A-061E-41F9-8DB9-60D26070DFCAQ33396155-DF7790DE-A651-4761-89BF-BD55C1AAEDA1Q33404631-020C7318-F557-4468-B416-0A8A4AF51737Q33647250-3CF018AE-95FB-4919-A45F-6D2DAF22A51DQ34391547-B69FB05B-014C-4E82-B95E-DF42E2973023Q35764202-36D98846-08CF-4FDF-B3B9-965504054593Q35828225-B7839C93-1AA2-40EE-AA3E-820ED37E32C1Q36465966-5DBB7697-8C3B-4188-8546-9A2FCDD6117CQ36651312-D6C45AA3-A563-4D20-89EC-5196E4BF75A5Q37886280-30A69CC6-490B-4ACD-AC5A-0A20C815EF8FQ38205249-59E2C857-E2BB-42E8-B60C-D7CFBB40857DQ38486979-916C582F-3948-4695-A51A-7502FD013595Q39093905-F2984431-8CC4-4313-BBDD-8D456F3AD655Q40116294-A7C22DDF-F7D1-472C-BDD3-7D61617FDD74Q40265125-AF971574-4E37-4333-BCE8-26808457C230Q40598199-85701038-B150-49CC-AE32-FD6825DDE8BBQ41654330-26074038-051B-438A-BA94-18F40B9A115FQ42251240-3C61BEF5-849A-4008-936F-F5DF7D5D4CB9Q42789580-B95D8660-D6BB-4FC2-9274-4923A4BA1BE2Q42947269-45B7DE28-95F1-489C-A168-2CEE6447EA08Q42986270-78157AAC-3A67-4783-A106-F1A53A37F81CQ43041364-9B456001-D577-4BD1-8E22-2DF6FF77FFB0Q43202400-2C631699-D10C-424B-8469-321DA11A9ACAQ43452857-7F1020AA-299C-408A-A676-0C465D0D60F3Q43895344-BC620436-25B8-4D8C-8A54-F5EE9409572FQ43962964-0EC872D3-3EAE-4DF3-8A78-56E6A6EC0AA3Q44156507-9D0D674B-9740-437D-AFE6-691837197287Q44208222-272F3912-BC5B-422D-91E0-D12C134DBA66Q44232847-1B2D5C20-B2F7-4A7F-9383-1A88C538B9B8Q44296215-5E23D32E-211D-46F3-AC7A-AFDFDCCC8360Q44739676-62832F18-B1C6-4F10-AC45-9A2C03EB02F0Q45066116-3196D04C-4561-4A15-9FF1-27AB96F99772Q45191588-6142FFED-3F22-45E0-A0DE-C018656DDDD9Q45731750-57B78D0A-28C1-48DF-A13A-25BBF54AB568Q50131677-BE94F29A-438B-410A-AB57-ECE5F5D4154EQ50280132-AE8EA2B8-7976-42BE-B6A6-C749FB0C484AQ50551858-4009BE64-3578-4E6E-A565-8C31C3594A2EQ50552231-F3A544BD-4AC3-4C06-9688-3FC76DBC7336Q50553196-6B3B3F18-68B1-4AE7-8DE8-26ADF36DF42D
P50
description
Polish physician, infectious diseases specialist
@en
Pools arts
@nl
polski lekarz chorób zakaźnych
@pl
name
Waldemar Halota
@ast
Waldemar Halota
@en
Waldemar Halota
@es
Waldemar Halota
@ga
Waldemar Halota
@nl
Waldemar Halota
@pl
Waldemar Halota
@sl
Waldemar Halota
@sq
type
label
Waldemar Halota
@ast
Waldemar Halota
@en
Waldemar Halota
@es
Waldemar Halota
@ga
Waldemar Halota
@nl
Waldemar Halota
@pl
Waldemar Halota
@sl
Waldemar Halota
@sq
prefLabel
Waldemar Halota
@ast
Waldemar Halota
@en
Waldemar Halota
@es
Waldemar Halota
@ga
Waldemar Halota
@nl
Waldemar Halota
@pl
Waldemar Halota
@sl
Waldemar Halota
@sq
P214
P106
P21
P214
P27
P31
P569
1947-09-19T00:00:00Z
P735
P7859
lccn-no2011162208